The intraperitonial administration of 0.1 and 0.2 mg/Kg b.w. CuB resulted in a dose-dependent inhibition of tumor angiogenesis in the VEGF-induced matrigel plugs. The gene discussed is VEGFA; the disease is neoplasm.